Equity Profile

SLNO

Soleno Therapeutics, Inc.

Health CareBiotechnology$2.8B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:44 PM EDT

Soleno Therapeutics Misses on EPS, Stock Up 0.02%

Metric	Actual	Expected	Surprise
EPS	$0.59	N/A	-19.40%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Soleno Therapeutics Misses on EPS, Stock Up 0.02%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.59	N/A	-19.40%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Soleno Therapeutics reported an EPS of $0.59, which was below expectations, leading to a slight increase in stock price of 0.02%. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The market's muted reaction suggests that investors may have anticipated the EPS miss.

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, crucial for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $3 billion, it operates in the health care sector, where advancements in treatments can significantly impact patient lives and market dynamics.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In the last quarter, Soleno reported an EPS of $0.80, exceeding expectations by 25.39%. The stock reacted positively, gaining 4.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Soleno's upcoming earnings are mixed, with no analyst estimates available. Investors will be keen to see if the company can maintain its recent momentum.

Bull Case

If Soleno continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its therapies and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026, and how does it compare to previous quarters?

The EPS figure will be critical in assessing the company's profitability and could influence investor sentiment significantly.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is essential for understanding the company's market position and future potential, making it a focal point for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Soleno's therapies to gain traction in the market, given their recent successes.

Supporting Evidence

The company has a history of surprising on the upside, with a 63% EPS beat rate.

Options pricing suggests a higher expected move than historical averages, indicating potential for volatility.

Recent positive trends in the biotech sector could bode well for Soleno's upcoming performance.

Key Risk

If the EPS comes in above $0.85, it could challenge the current cautious sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate whether the company can sustain its growth trajectory.

Bull Confirmed If

An EPS of $0.85 or higher would confirm strong profitability and growth.

Bear Confirmed If

An EPS below $0.70 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 4.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±5.1% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

91.7%

Calls (1.3M)P/C Ratio: 0.01Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 1.6%, confirming the bullish outlook.

In-Line / Cautious

If results are in line but management provides cautious guidance, the stock may see limited movement as investors digest the news.

Miss

A miss could lead to a decline of approximately 1.19%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapy developments or clinical trial results.
2Management's outlook on market demand for their products.
3Details on cost management strategies and their impact on profitability.
4Insights into competitive positioning within the biotechnology sector.
5Any changes in regulatory environment that could affect product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

DHCReported

Diversified Healthcare Trust

RecapView

May4

BSMReported

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, crucial for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In the last quarter, Soleno reported an EPS of $0.80, exceeding expectations by 25.39%. The stock reacted positively, gaining 4.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Soleno's upcoming earnings are mixed, with no analyst estimates available. Investors will be keen to see if the company can maintain its recent momentum.

Bull Case

If Soleno continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its therapies and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026, and how does it compare to previous quarters?

The EPS figure will be critical in assessing the company's profitability and could influence investor sentiment significantly.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is essential for understanding the company's market position and future potential, making it a focal point for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Soleno's therapies to gain traction in the market, given their recent successes.

Supporting Evidence

The company has a history of surprising on the upside, with a 63% EPS beat rate.

Options pricing suggests a higher expected move than historical averages, indicating potential for volatility.

Recent positive trends in the biotech sector could bode well for Soleno's upcoming performance.

Key Risk

If the EPS comes in above $0.85, it could challenge the current cautious sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate whether the company can sustain its growth trajectory.

Bull Confirmed If

An EPS of $0.85 or higher would confirm strong profitability and growth.

Bear Confirmed If

An EPS below $0.70 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 4.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±5.1% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

91.7%

Calls (1.3M)P/C Ratio: 0.01Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 1.6%, confirming the bullish outlook.

In-Line / Cautious

If results are in line but management provides cautious guidance, the stock may see limited movement as investors digest the news.

Miss

A miss could lead to a decline of approximately 1.19%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapy developments or clinical trial results.
2Management's outlook on market demand for their products.
3Details on cost management strategies and their impact on profitability.
4Insights into competitive positioning within the biotechnology sector.
5Any changes in regulatory environment that could affect product approvals.